AU7709300A - Drug discovery using gene expression profiling - Google Patents

Drug discovery using gene expression profiling

Info

Publication number
AU7709300A
AU7709300A AU77093/00A AU7709300A AU7709300A AU 7709300 A AU7709300 A AU 7709300A AU 77093/00 A AU77093/00 A AU 77093/00A AU 7709300 A AU7709300 A AU 7709300A AU 7709300 A AU7709300 A AU 7709300A
Authority
AU
Australia
Prior art keywords
gene expression
drug discovery
expression profiling
profiling
discovery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU77093/00A
Inventor
Yih Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Linden Technologies Inc
Original Assignee
Linden Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Linden Technologies Inc filed Critical Linden Technologies Inc
Publication of AU7709300A publication Critical patent/AU7709300A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809Methods for determination or identification of nucleic acids involving differential detection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00ICT programming tools or database systems specially adapted for bioinformatics
    • G16B50/20Heterogeneous data integration
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00ICT programming tools or database systems specially adapted for bioinformatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Databases & Information Systems (AREA)
  • Bioethics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU77093/00A 1999-09-24 2000-09-22 Drug discovery using gene expression profiling Abandoned AU7709300A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15610599P 1999-09-24 1999-09-24
US60156105 1999-09-24
PCT/US2000/026050 WO2001020998A1 (en) 1999-09-24 2000-09-22 Drug discovery using gene expression profiling

Publications (1)

Publication Number Publication Date
AU7709300A true AU7709300A (en) 2001-04-24

Family

ID=22558115

Family Applications (1)

Application Number Title Priority Date Filing Date
AU77093/00A Abandoned AU7709300A (en) 1999-09-24 2000-09-22 Drug discovery using gene expression profiling

Country Status (2)

Country Link
AU (1) AU7709300A (en)
WO (1) WO2001020998A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501911B2 (en) 1999-02-24 2013-08-06 Biomarck Pharmaceuticals, Ltd Methods of reducing inflammation and mucus hypersecretion
US7544772B2 (en) 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US6964850B2 (en) 2001-11-09 2005-11-15 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
WO2004007681A2 (en) * 2002-07-12 2004-01-22 Duke University Genetic susceptibility genes for asthma and atopy and asthma-related and atopic-related phenotypes
US7807465B2 (en) 2004-10-27 2010-10-05 Duke University Methods for identifying an individual at increased risk of developing coronary artery disease
US7790390B2 (en) 2004-10-27 2010-09-07 Duke University Methods for identifying an individual at increased risk of developing coronary artery disease
NZ577196A (en) 2005-01-20 2011-06-30 Biomarck Pharmaceuticals Ltd Mucin hypersecretion inhibitors based on the structure of MANS and methods of use
CN103990111B (en) 2006-07-26 2016-08-31 拜欧马克医药有限公司 Reduce the method for inflammatory mediator release and can be used for the peptide of the method

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6114114A (en) * 1992-07-17 2000-09-05 Incyte Pharmaceuticals, Inc. Comparative gene transcript analysis
AU8382998A (en) * 1997-07-02 1999-01-25 Genzyme Corporation P53 influenced gene expression
AU9200298A (en) * 1997-08-22 1999-03-16 Yale University A process to study changes in gene expression in stem cells
AU9200398A (en) * 1997-08-22 1999-03-16 Yale University A process to study changes in gene expression in granulocytic cells
AU759785C (en) * 1998-05-05 2003-12-04 Gene Logic, Inc. A process to study changes in gene expression in T lymphocytes
JP2002530092A (en) * 1998-11-13 2002-09-17 キュラゲン コーポレイション Compositions and methods related to the peroxisome proliferator-activated receptor-α-mediated pathway

Also Published As

Publication number Publication date
WO2001020998A1 (en) 2001-03-29

Similar Documents

Publication Publication Date Title
AU1071301A (en) Pharmaceutical compounds
AU5259100A (en) Medicament
AU3569800A (en) Pyrimidine compounds with pharmaceutical activity
AU2002259196A1 (en) Gene expression profiling
AU1469001A (en) Capacitive mouse
AU6281100A (en) Novel diketopiperazines
AU7815000A (en) Targeted drug activation
AU5073400A (en) Sulfonamide compounds with pharmaceutical activity
AUPP938799A0 (en) Electrodes
AU1132601A (en) Feature interactions
AU6715600A (en) Pharmaceutical formulations
AUPQ262599A0 (en) Gene expression
AU1586500A (en) Computer arrangement using non-refreshed dram
AU7709300A (en) Drug discovery using gene expression profiling
AU1645700A (en) Oenothein medicaments
AU4977300A (en) Pharmaceutical formulations
AU5722900A (en) Pharmaceutical compounds
AU6036100A (en) New pharmaceutically active compounds
AU1385801A (en) Pharmaceutical formulations
AU7606100A (en) Gene expression profiles
AU2376200A (en) Insulin-synthesis genes
AU7318700A (en) Novel transaldolase gene
AU2732000A (en) Reverse gene therapy
AU2001247444A1 (en) Erbeta-mediated gene expression
AUPQ749100A0 (en) New epilespy gene

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase